Baxter International (BAX)

• Market cap: $15.1B
• 1 day: 2.08%
• 5 days: -1.73%
• 1 month: -9.59%
• 3 months: -23.36%
• 6 months: -13.24%
• Year to date: -24.07%
• 1 year: -23.58%
• 5 years: -64.24%
• 10 years: -60.51%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.

Employees: 60,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

19% more call options, than puts

Call options by funds: $132M | Put options by funds: $111M

14% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 8 (+1) [Q3]

13% more capital invested

Capital invested by funds: $15.5B [Q2] → $17.5B (+$2.02B) [Q3]

10% more first-time investments, than exits

New positions opened: 116 | Existing positions closed: 105

1% more funds holding

Funds holding: 863 [Q2] → 874 (+11) [Q3]

0.19% less ownership

Funds ownership: 90.78% [Q2] → 90.59% (-0.19%) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 299 | Existing positions reduced: 310

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 19% upside
• Avg. target: $37 24% upside
• High target: $38 29% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target	19% upside $35	Neutral Maintained	11 Dec 2024
Stifel Rick Wise 62% 1-year accuracy 18 / 29 met price target	29% upside $38	Buy Maintained	11 Nov 2024